Stay updated on Olpasiran Study: Clinical Trial for Lipoprotein(a) Reduction
Sign up to get notified when there's something new on the Olpasiran Study: Clinical Trial for Lipoprotein(a) Reduction page.

Latest updates to the Olpasiran Study: Clinical Trial for Lipoprotein(a) Reduction page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedRevision added: v3.5.0; revision v3.4.3 removed.SummaryDifference0.0%

- Check18 days agoChange DetectedUpdated revision from v3.4.2 to v3.4.3. The update likely includes minor patches and UI improvements.SummaryDifference0.0%

- Check25 days agoNo Change Detected
- Check47 days agoChange DetectedAdded Revision: v3.4.2 tag and removed the government funding notice about operations status; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check54 days agoChange DetectedAdded a site-wide funding notice and updated the page revision from v3.4.0 to v3.4.1.SummaryDifference0.3%

- Check61 days agoChange DetectedAdded a 'Show glossary' option on the page. Updated metadata labels to 'Last Update Submitted that Met QC Criteria', 'No FEAR Act Data', and the revision to v3.4.0.SummaryDifference0.2%

- Check97 days agoChange DetectedExpanded the study location data with numerous regional and country locations (e.g., California, Florida, Georgia, Kansas, Maryland, New York, North Carolina, Ohio, Texas; New South Wales, Queensland, Victoria, Western Australia; Ontario, Quebec; Chiba, Hokkaido, Ishikawa-ken, Saitama) and removed the HHS Vulnerability Disclosure link. Revision updated to v3.3.3.SummaryDifference2%

Stay in the know with updates to Olpasiran Study: Clinical Trial for Lipoprotein(a) Reduction
Enter your email address, and we'll notify you when there's something new on the Olpasiran Study: Clinical Trial for Lipoprotein(a) Reduction page.